Report
Arrowhead's ARO-MAPT shows deep tau protein reductions in early trial of healthy volunteers
Arrowhead reports a 73% mean spinal-fluid tau reduction on day 105, with a maximum individual reduction of 85%.
TLDR
In interim Phase 1/2a results from healthy volunteers, Arrowhead says its under-the-skin ARO-MAPT injection delivered siRNA across the blood-brain barrier. It reported a mean 73% reduction in spinal-fluid tau on day 105 and a maximum individual reduction of 85%. The results do not yet show whether the drug protects memory.
Combined views
8
2 Sources, first seen ago
